Just in time to assure a decision before CVR deadline, Bristol Myers Squibb files NDA for Celgene/bluebird CAR-T
A new CAR-T therapy may be coming. And maybe $9 per share for Celgene investors, too.
Bristol Myers Squibb announced they submitted an NDA for …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
